944582-92-7

Basic information

• Product Name: 5-Bromo-2-(4-Boc-piperazin-1-yl)-4-methylpyridine
• Synonyms: 5-Bromo-2-(4-Boc-piperazin-1-yl)-4-methylpyridine;5-Bromo-2-[4-(N-Boc)piperazin-1-yl]-4-methylpyridine;1-BOC-4-(5-Bromo-4-methyl-2-pyridinyl)piperazine;t-Butyl 4-(5-Bromo-4-methyl-2-pyridinyl)piperazine-1-carboxylate;tert-Butyl 4-(5-broMo-4-Methylpyridin-2-yl)piperazine-1-carboxylate
• CAS NO: 944582-92-7
• Molecular Formula: C15H22BrN3O2
• Molecular Weight: 356.26
• Product Categories: Organohalides;Pyridine
• Mol File: 944582-92-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 5-Bromo-2-(4-Boc-piperazin-1-yl)-4-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-(4-Boc-piperazin-1-yl)-4-methylpyridine(944582-92-7)
• EPA Substance Registry System: 5-Bromo-2-(4-Boc-piperazin-1-yl)-4-methylpyridine(944582-92-7)

Safety Data

• Hazardous Substances Data: 944582-92-7(Hazardous Substances Data)

Usage

Description

5-Bromo-2-(4-Boc-piperazin-1-yl)-4-methylpyridine is a pyridine derivative with the molecular formula C16H23BrN4O2. It features a bromine atom, a Boc-protected piperazine ring, and a methyl group, making it a versatile intermediate in the synthesis of pharmaceuticals and agrochemicals.

Uses

Used in Pharmaceutical Synthesis:
5-Bromo-2-(4-Boc-piperazin-1-yl)-4-methylpyridine is used as a key intermediate for the development of various pharmaceuticals. Its Boc-protected piperazine moiety allows for further modification and functionalization, contributing to the creation of new drug candidates.
Used in Agrochemical Production:
In the agrochemical industry, 5-Broc-2-(4-Boc-piperazin-1-yl)-4-methylpyridine serves as an essential building block for the synthesis of various agrochemicals. Its reactivity and functional groups enable the production of effective compounds for agricultural applications.
Safety and Handling:
5-Bromo-2-(4-Boc-piperazin-1-yl)-4-methylpyridine should be handled with care due to its potential to cause irritation and harmful effects if ingested or inhaled. It is recommended for use only in a laboratory setting by trained professionals who follow proper safety protocols and handling procedures.

Upstream product

• 3430-18-0 2,5-dibromo-3-methylpyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 864830-16-0 5-bromo-2-fluoro-4-methyl-pyridine 

Downstream Products

• 1073355-13-1 tert-butyl 4-[4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]piperazine-1-carboxylate 

Relevant articles and documents

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES

Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R1, R2, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.